Patents by Inventor Santosh Sinha

Santosh Sinha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF
    Publication number: 20220402866
    Abstract: Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.
    Type: Application
    Filed: December 8, 2021
    Publication date: December 22, 2022
    Inventors: Christopher D. Hein, Tien T. Duong, Santosh Sinha, Ling Li, Jeremiah H. Nguyen, David W. Old, Robert Burk, Veena Viswanath, Sandhya Rao, John E. Donello
  • PHARMACOLOGICAL AGENTS FOR TREATING PROTEIN AGGREGATION DISEASES OF THE EYE
    Publication number: 20220241247
    Abstract: Methods of treating presbyopia or cataract in a subject in need thereof are provided. The methods require administering to the subject an effective amount of a composition comprising a compound that inhibits the formation of high molecular weight aggregates of human ?-A-crystallin. A method of preventing and/or treating transthyretin (TTR)-associated amyloidosis using certain of these compounds is also provided.
    Type: Application
    Filed: June 1, 2020
    Publication date: August 4, 2022
    Inventors: Sridhar Govinda PRASAD, Marshall Clarke PETERMAN, Santosh SINHA
  • 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof
    Patent number: 11208377
    Abstract: Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: December 28, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Christopher D. Hein, Tien T. Duong, Santosh Sinha, Ling Li, Jeremiah H. Nguyen, David W. Old, Robert Burk, Veena Viswanath, Sandhya Rao, John E. Donello
  • 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF
    Publication number: 20190047947
    Abstract: Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.
    Type: Application
    Filed: August 14, 2018
    Publication date: February 14, 2019
    Inventors: Christopher D. Hein, Tien T. Duong, Santosh Sinha, Ling Li, Jeremiah H. Nguyen, David W. Old, Robert Burk, Veena Viswanath, Sandhya Rao, John E. Donello
  • Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors
    Patent number: 7476673
    Abstract: Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RAR? agonist retinoids, such as skin related diseases, including but not limited to acne and psoriasis.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: January 13, 2009
    Assignee: Allergan, Inc.
    Inventors: Kwok Yin Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha A. Chandraratna
  • Disubstituted chalcone oximes having RAR? retinoid receptor antagonist activity
    Patent number: 7432388
    Abstract: Compounds of the formula where the variables have the values described in the specification are antagonists of RAR?retinoid receptors.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: October 7, 2008
    Assignee: Allergan, Inc.
    Inventors: Kwok Yin Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha A. Chandraratna
  • Disubstituted chalcone oximes having RARgamma retinoid receptor antagonist activity
    Publication number: 20080097119
    Abstract: Compounds of the formula where the variables have the values described in the specification are antagonists of RAR?, retinoid receptors.
    Type: Application
    Filed: June 4, 2007
    Publication date: April 24, 2008
    Inventors: Kwok Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha Chandraratna
  • Disubstituted chalcone oximes having RAR? retinoid receptor antagonist activity
    Patent number: 7253319
    Abstract: Compounds of the formula where the variables have the values described in the specification are antagonists of RAR? retinoid receptors.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: August 7, 2007
    Assignee: Allergan, Inc.
    Inventors: Kwok Yin Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha A. Chandraratna
  • Automatic power connector system machine
    Publication number: 20060125238
    Abstract: The subject-matter of the present invention is a system for the generation of electrical energy by generating a high speed pulse to utilize and condense electrical energy, eliminating any possible use of external energy or a mechanical thrust, consist; a connector device being propelled using a high speed source motor (1), exhibiting at least a pair of active phases, on both side of it as a minimum demand of the system circuit, each pair working in opposite of other's function and connected by a phase connector device (3) moving with the speed of source motor (1), on each side, organized in a parallel, round or any other shape/style of Insulated Chassis. The system thus generates a benefit of (A) unique equilibrium in the source and target of the energy utilized, (B) multiple utilization of single phase at almost the same time.
    Type: Application
    Filed: November 2, 2005
    Publication date: June 15, 2006
    Inventors: Kalishwar Das, Santosh Sinha
  • 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
    Patent number: 6936636
    Abstract: Compounds of the formula: where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of reducing serum thyroxine levels and transiently increasing triglyceride levels.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: August 30, 2005
    Assignee: Allergan, Inc.
    Inventors: Santosh Sinha, Kwok Yin Tsang, Smita Bhat, Roshantha A. Chandraratna
  • Disubstituted chalcone oximes having RARy retinoid receptor antagonist activity
    Publication number: 20050165095
    Abstract: Compounds of the formula where the variables have the values described in the specification are antagonists of RAR? retinoid receptors.
    Type: Application
    Filed: December 23, 2004
    Publication date: July 28, 2005
    Inventors: Kwok Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha Chandraratna
  • Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors
    Publication number: 20050148590
    Abstract: Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RAR? agonist retinoids, such as skin related diseases, including but not limited to acne and psoriasis.
    Type: Application
    Filed: December 17, 2004
    Publication date: July 7, 2005
    Inventors: Kwok Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha Chandraratna
  • 7-[(7-ALKOXY)-CHROM-3-EN-6-YL]-HEPTATRIENOIC ACID AND 7-[(3-ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL]-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY
    Publication number: 20050096380
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of transiently increasing triglyceride levels and reducing serum thyroxine levels.
    Type: Application
    Filed: October 29, 2003
    Publication date: May 5, 2005
    Inventors: Richard Beard, Tien Duong, Janet Takeuchi, Ling Li, Kwok Tsang, Xiaoxia Liu, Jayasree Vasudevan, Liming Wang, Santosh Sinha, Haiqing Yuan, Roshantha Chandraratna
  • 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
    Publication number: 20050004213
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of reducing serum thyroxine levels and transiently increasing triglyceride levels.
    Type: Application
    Filed: June 26, 2003
    Publication date: January 6, 2005
    Inventors: Santosh Sinha, Kwok Tsang, Smita Bhat, Roshantha Chandraratna
  • [3-(C5-14ALKYL-2-OXO-1,2,3,4-TETRAHYDRO-QUINOLIN-6-YL)-3-OXO-PROPENYL]-PHENYL AND [3-(C5-14ALKYL-2-OXO-1,2,3,4- TETRAHYDRO-QUINOLIN-6-YL)-3-OXO-PROPENYL]-HETEROARYL DERIVATIVES HAVING ANTI-TUMOR ACTIVITY
    Patent number: 6683092
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification have anti-tumor activity.
    Type: Grant
    Filed: April 9, 2003
    Date of Patent: January 27, 2004
    Assignee: Allergan, Inc.
    Inventors: Kwok Yin Tsang, Santosh Sinha, Smita Bhat, Xiaoxia Liu, Roshantha A. Chandraratna